Galytx was delighted to be one of the companies presenting to the
international investment community at the LSX Investival Event in London

November 2024, London

 Insights from industry insiders into the biotech investment landscape and trends in exits were encouraging and bode well for the Galytx business model and vision. It was also a pleasure to meet with some of the team who led the Innovate UK/CRUK supported Oncology Development Programme that helped us to define our company focus and strategy.

Galytx is pleased to be an industrial partner in the recently launched Hub for Long-Acting Therapeutics funded by EPSRC

Galytx is pleased to be an industrial partner in the recently launched  Hub for Long-Acting Therapeutics (LATs) at the University of Liverpool .LATs are set to revolutionise how diseases are treated and managed by replacing weeks or even months of pill taking with a single administered dose. The Hub is supported by £11m funding from EPSRC and will drive research, public and patient engagement, and the translational infrastructure required for the development and manufacture of new LATs to ensure the UK is at the forefront of this strategically important healthcare area. Participation in this cutting edge initiative will ensure that future formulations of galectin-3 targeted therapies for chronic conditions are able to benefit from the advantages of long-acting delivery

Galytx received award from Innovate UK's Cancer Therapeutics programme

Galytx has received funding from Innovate UK to accelerate its development of galectin-3-targeted therapeutics in cancer